KBC Group’s iShares Biotechnology ETF IBB Stock Holding History

KBC Group’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,654	Closed	-$250K	–	1296
2021 Q1	$250K	Buy	+1,654	New	+$263K	﹤0.01%	1153

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

KBC Group's IBB Position: Q2 2021 in Review

KBC Group sold out of iShares Biotechnology ETF (IBB) in Q2 2021, closing a stake of 1,654 shares — an estimated $250K sold.

KBC Group first reported a position in IBB in Q1 2021 and held it in 1 quarter. The position peaked at $250K in Q1 2021. 863 funds tracked by Wall St. Rank hold IBB as of Q2 2021.

KBC Group reported no remaining iShares Biotechnology ETF position as of Q2 2021 after selling out during the quarter.
KBC Group sold 1,654 iShares Biotechnology ETF shares in Q2 2021, an estimated $250K.
KBC Group first reported a position in iShares Biotechnology ETF in Q1 2021 and held it in 1 quarter.
KBC Group's iShares Biotechnology ETF position peaked at $250K in Q1 2021.
863 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2021.

Based on KBC Group's 13F filing for Q2 2021, filed 11 Aug 2021.